factor VIII


Also found in: Thesaurus, Medical, Legal, Financial, Acronyms, Encyclopedia, Wikipedia.
Related to factor VIII: Factor VIII deficiency

factor VIII

n.
A protein substance in blood plasma that is an essential part of the blood-clotting process. Most cases of hemophilia are caused by a genetic defect that leads to a deficiency of this factor. Also called antihemophilic factor.

factor VIII

n
(Biochemistry) a protein that participates in the clotting of blood. It is extracted from donated serum and used in the treatment of the commonest type of haemophilia, in which it is absent

factor VIII


n.
an enzyme of blood plasma that is essential to normal blood clotting: lacking or deficient in hemophiliacs.
[1960–65]
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.factor VIII - a coagulation factor (trade name Hemofil) whose absence is associated with hemophilia Afactor VIII - a coagulation factor (trade name Hemofil) whose absence is associated with hemophilia A
clotting factor, coagulation factor - any of the factors in the blood whose actions are essential for blood coagulation
References in periodicals archive ?
Sattari said on Sunday that a foreign company had deliberately reduced prices for an anti-hemophilic medicine known as Factor VIII in order to prevent an Iranian company to sell the drug to patients inside the country.
* Long-term follow-up from four phase III studies (HAVEN studies) shows Hemlibra's sustained efficacy and safety in people with hemophilia A, with and without factor VIII inhibitors.
- US-based biotechnology company Genentech, a member of Switzerland's Roche Group (SIX: RO) (OTCQX: RHHBY), has presented new data for Hemlibra (emicizumab-kxwh) across multiple pivotal studies in people with hemophilia A with and without factor VIII inhibitors at the International Society on Thrombosis and Haemostasis 2019 Congress on July 6-10 in Melbourne, Australia, the company said.
Roche announced new data for Hemlibra (emicizumab) across multiple pivotal studies in people with haemophilia A with and without factor VIII inhibitors at the International Society on Thrombosis and Haemostasis (ISTH) 2019 Congress on 6-10 July in Melbourne, Australia.
Substantial Reduction in excess of 92% in Mean Bleed Rate Requiring Factor VIII Infusions; Sustained over the Period of Observation (3 Years in High Dose and 2 Years in Low Dose)
As of May 28, 2019, eight patients in the 20-patient cohort of the Phase 3 GENEr8-1 study achieved Factor VIII levels of 40 international units per deciliter, or IU/dL, or more, at 23 to 26 weeks, meeting the pre-specified criteria for Factor VIII activity levels.
Reportedly, the CHMP recommends Esperoct, the brand name for turoctocog alfa pegol, N8-GP, to be indicated for prophylaxis and on-demand treatment of bleeding as well as for surgical procedures in adolescents (>=12 years of age) and adults with haemophilia A (congenital factor VIII deficiency).
Objective: To determine the frequency and levels of factor VIII inhibitors in known haemophilics in our population.
29, 2018 (HealthDay News) -- For patients with hemophilia A without factor VIII inhibitors, emicizumab prophylaxis leads to a significantly reduced bleeding rate, according to a study published in the Aug.
NORDIC BUSINESS REPORT-February 28, 2018-Novo Nordisk files for regulatory approval of long-acting factor VIII (N8-GP) in US and EU
The treatment of hemophilia may involve prophylaxis, management of bleeding episodes, treatment of factor VIII (FVIII) inhibitors, and treatment and rehabilitation of hemophilia synovitis.
Haemophilia is a rare condition where patients present with abnormal bleeding and other complications of bleeding due to genetic or acquired deficiency of coagulation factor VIII (Haemophilia A) or factor IX (Haemophilia B).